Last scanned
Domain Age
Daily Visitors
Global Rank
Updated:
Secondary Acute Myeloid Leukemia (sAML) Treatment | VYXEOS® (daunorubicin and cytarabine)
Find information on VYXEOS® (daunorubicin and cytarabine), a treatment for adults for two types of newly-diagnosed AML, t-AML and AML-MRC. See Safety Info & Warning about not substituting with other daunorubicin and/or cytarabine-containing products.
This website is hosted with Amazon Technologies Inc., which reserves the following IP addresses for vyxeos.com: 52.88.89.3. Moreover, DNS used with this website include dns1.cscdns.net, dns2.cscdns.net. Subnet identifier ranges from 52.84.0.0 to 52.95.255.255. Classless Inter-Domain Routing (CIDR) is 52.88.0.0/13, 52.84.0.0/14. ARIN net type is Direct Allocation.
Last scanned
Domain Age
Daily Visitors
Global Rank
dns1.cscdns.net
dns2.cscdns.net
{{value}}
2014-08-11
2024-08-11
CSC CORPORATE DOMAINS, INC.
{{value}}
The registrar of vyxeos.com is CSC CORPORATE DOMAINS, INC. and the name expires on 2024-08-11. According to open source data, you can reach the owner at dns-admin@cscglobal.com but please make sure you have a good reason for unsolicited messages. Their country of residence is United States of America.
N/A
534
N/A
N/A
781.4K
534
N/A
N/A
N/A
N/A
N/A
N/A